1,1,1-Trifluoro-2,2-dimethylhexane

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1,1,1-Trifluoro-2,2-dimethylhexane
• 英文别名: 1,1,1-trifluoro-2,2-dimethylhexane
• 化学式: C₈H₁₅F₃
• 分子量: 168.2
• InChiKey: SEFTUHUKCICIEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US11066417B2

  公开（公告）日：2021-07-20

  Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

  式 (I) 的化合物： 公开了前述化合物的药学上可接受的盐、前述化合物的氚代衍生物以及前述化合物的代谢物。还公开了包含上述物质的药物组合物、使用上述物质治疗囊性纤维化的方法以及上述物质的制造方法。
• Organic electroluminescent materials and devices
  申请人：Universal Display Corporation

  公开号：US11233203B2

  公开（公告）日：2022-01-25

  The present disclosure is directed to cyclometalated metal compounds containing novel ligands having unique fused rings. The inventive compounds are expected to exhibit unique photophysical and electronic properties and are useful in an organic electroluminescence device to improve the performance.

  本公开涉及含有具有独特熔环的新型配体的环金属化合物。本发明的化合物有望表现出独特的光物理和电子特性，可用于有机电致发光器件以提高其性能。
• MACROCYCLES AS MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS THEREOF, THEIR USE IN THE TREATMENT OF CYCSTIC FIBROSIS, AND PROCESS FOR MAKING THEM
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP3752510B1

  公开（公告）日：2022-12-07
• Modulators of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods of Treatment, and Process for Making the Modulators
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20190248809A1

  公开（公告）日：2019-08-15

  Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
• ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
  申请人：UNIVERSAL DISPLAY CORPORATION

  公开号：US20220135605A1

  公开（公告）日：2022-05-05

  Provided are phenylthienothiazole containing compounds. The compound of the present invention comprises a first phenylthienothiazole-derived ligand L A according to Formula I as described herein which is coordinated to Ir to form a 5-membered chelate ring. Also provided are formulations comprising these compounds. Further provided are OLEDs and related consumer products that utilize these compounds.